ADx logo

news and events

IWT project funding for generation of antibodies for human tau

16/12/2011 news funding, News

Participation agreement with the Critical Path Institute, USA

23/11/2011 news agreement, News

License agreement with KU Leuven for the development of antibodies against p-tau

08/11/2011 news academic collaboration, News

Today the recently founded  company ADx NeuroSciences NV entered into a license agreement with KU Leuven, the academic founder of ADx NeuroSciences. The license agreement grants ADx NeuroSciences exclusive worldwide rights to further develop and commercialise certain antibodies which selectively bind phosphorylated Tau aggregates. ADx NeuroSciences is a new biotech company that focuses on the development of novel (bio)markers for use in the diagnosis of dementia, such as Alzheimer’s, Parkinson’s and other neurodegenerative diseases.

Read More